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Cytotoxic T-lymphocyte antigen-4 (CTLA-4) plays an essential role in T cell homeostasis by restraining im-
mune responses. AG and GG genotypes of donor CTLA-4 SNP rs4553808 in patients after unrelated donor
hematopoietic stem cell transplantations (HSCT) have been shown to be an independent predictor of inferior
relapse-free survival (RFS) and overall survival (OS) compared with those with the AA genotype, in single-
center studies. We tested the hypothesis that SNP rs4553808 is associated with RFS, OS, nonrelapse mor-
tality (NRM) and the cumulative incidence of acute graft-versus-host disease (GVHD) and chronic GVHD in
adults with acute myeloid leukemia and advanced myelodysplastic syndrome undergoing a ﬁrst 8/8 or 7/8
HLA-matched unrelated donor HSCT. Multivariable analysis adjusting for relevant donor and recipient
characteristics showed no signiﬁcant association between SNP rs4553808 and OS, RFS, NRM, and incidence of
acute and chronic GVHD. An exploratory analysis of other CTLA-4 SNPs, as well as studying the interaction
with antithymocyte globulin, also demonstrated no signiﬁcant associations. Our results indicate that CTLA-4
SNPs are not associated with HSCT outcomes.
Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) is curative
therapy for many malignant hematologic diseases. However,
the success of HSCT is often limited by disease relapse and
graft-versus-host disease (GVHD). There are currently no
established biologic predictors of transplantation outcomes.
Understanding how to achieve the optimal balance between
a potent graft-versus-tumor (GVT) effect and minimizing the
risk of GVHD remains elusive. Both GVT and GVHD are de-
pendent on maintaining T cell homeostasis, which requires
regulation of an intricate system of immunologic checks and
balances. One of the regulatory molecules that serves as an
important immunologic checkpoint is cytotoxic T-lymphocyteedgments on page 903.
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14.03.005antigene4 (CTLA-4),whichprimarily functions in inhibitionof
T cell activation. CTLA-4 is a member of the immunoglobulin
superfamily, and it, along with other regulatory molecules,
such as programmed death-1 (PD-1), plays an important role
in regulation of peripheral tolerance [1]. Upon recognition of
an antigen by the T cell receptor, CTLA-4 competes with CD28
to bind with CD80/86. This signal, in turn, leads to inhibition
of downstream T cell activation and subsequently down-
regulates the immune response [2]. In clinical practice, this
mechanism of action has been harnessed as immunotherapy,
exempliﬁed by the drug ipilimumab, a CTLA-4eblocking
monoclonal antibody that augments the immune response
and improves overall survival (OS) in patients withmetastatic
melanoma [3].
The impact of SNPs of CTLA-4 has previously been
demonstrated in solid tumors. Speciﬁcally, the G allele of
rs4553808 has been associated with a positive response to
ipilimumab in patients with metastatic melanoma [4]. In
HSCT studies, CTLA-4 SNPs have been associated with dif-
ferences in relapse-free survival (RFS), OS, and GVHD, but
with discordant results from various investigators [5-9].
Previously, we have shown that donor SNP rs4553808 is an
Table 1
Patient, Transplant, and Donor Clinical Characteristics (N ¼ 780)
Characteristic n (%)
Recipient age, median (range), yr 50 (18-74)
Sex
Male 403 (52)
Female 377 (48)
Recipient race/ethnicity
Caucasian 706 (90)
African American 22 (3)
Hispanic 29 (4)
Other/multiple/decline 23 (3)
Disease
AML 624 (80)
MDS 156 (20)
Conditioning
Ablative 474 (61)
Reduced intensity 222 (28)
Nonmyeloablative 84 (11)
HLA match
8/8 matched 585 (75)
7/8 mismatch 195 (25)
GVHD prophylaxis
Tacrolimus þ MTX or MMF 480 (62)
Cyclosporine þ MTX 119 (15)
Other 181 (23)
Stem cell source
Peripheral blood 576 (74)
Bone marrow 204 (26)
HLA match
8/8 matched 513 (66)
7/8 (1 MM at HLA-A, -B, -C, or -DRB1) 267 (34)
Donor/recipient sex match
Male/male 276 (36)
Male/female 220 (29)
Female/male 117 (15)
Female/female 78 (21)
Donor age, median (range), yr 34 (18-61)
<20 yr 9 (1)
20-29 yr 242 (33)
30-39 yr 269 (36)
40-49 yr 174 (23)
50 and older 54 (7)
Donor race/ethnicity
Caucasian 639 (82)
African American 25 (3)
Hispanic 23 (4)
Other/multiple/decline 93 (12)
AML indicates acute myeloid leukemia; MDS, myelodysplastic syndrome;
MTX, methotrexate; MMF, mycoohenolate mofetil; MM, mismatch; GVHD,
graft-versus-host disease.
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unrelated donor HSCT, with patients who receive transplants
from donors with AG or GG genotypes having inferior RFS
and OS compared with those receiving transplants from
donors with the AA genotype [10]. We hypothesized that
these results could be validated in a larger, more homoge-
nous cohort of patients and, if validated, could be basis for
pretransplantation donor CTLA-4 genotyping as a risk-
stratiﬁcation tool that would aid in prediction of relapse
risk. Patients at high risk of relapse could be speciﬁcally
targeted for peri-transplantation immunomodulation or pre-
emptive therapies to reduce the risk of relapse.
Additionally, the interaction of CTLA-4 SNPs with use of
antithymocyte globulin (ATG) was also studied. In patients
undergoing a matched unrelated donor HSCT, ATG is often
used as part of GVHD prophylaxis. The efﬁcacy of ATG in
prophylaxis of GVHD is dependent on its ability to deplete
T-lymphocytes of the graft [11]. We hypothesized that ge-
netic variation in CTLA-4 may interact with the utilization of
the immunomodulatory drug ATG as part of the conditioning
regimen in unrelated donor transplantations. If an interac-
tion was observed, then that this could additionally facilitate
personalization of GVHD prophylaxis.
STUDY DESIGN
This studywas completed in collaborationwith the Center
for International Blood and Marrow Transplant Research
(CIBMTR) and the National Marrow Donor Program (NMDP).
The CIBMTR is an association of more than 500 trans-
plantation centersworldwide that collects statistical data and
maintains longitudinal follow-up on consecutive allogeneic
HSCTs. Data are submitted to the Statistical Center at the
Medical College of Wisconsin, and quality is ensured with
computerized checks, physician review of data, and onsite
audits of centers. Observational data collection by CIBMTR
was approved by the Institutional Review Board of the NMDP.
The primary objectiveswere to study the impact of genetic
variation in donor CTLA-4 SNP rs4553808 on RFS (deﬁned as
survival without relapse or death), OS (deﬁned as time to
death), and nonrelapsemortality (NRM) (deﬁned as any death
without evidence of disease relapse with relapse treated as a
competing risk). All data were censored at date of last follow-
up. Secondary endpoints included incidence of grades 2 to 4
acute GVHD and presence of chronic GVHD. The use of ATG
was considered in the analysis. An exploratory analysis of the
other 9 tagSNPs (rs231775, rs231779, rs11571315, rs231777,
rs3087243, rs16840252, rs231725, rs10197010, rs11571316) of
CTLA-4was also performed to investigate potential additional
associations.
Patients over the age of 18 with acute myeloid leukemia
(AML) and advanced myelodysplastic syndrome (MDS) in
ﬁrst or second complete remissionwho underwent a ﬁrst 8/8
or 7/8 HLA-matched unrelated donor allogeneic HSCT after
any conditioning regimen between 2002 and 2007 were
included in this study. HLA typing was veriﬁed using DNA-
based techniques, as previously described [12]. Any GVHD
prophylaxis was permitted with the exception of ex vivo
T cell depletion or use of in vivo/in vitro alemtuzumab. Based
on CIBMTR data, therewere 1463 cases eligible for this study.
A sample size calculation indicated 780 patients were
required to achieve 80% power to detect a signiﬁcance level
(alpha) of 0.005 (increased stringency due to multiple
testing) using a 2-sided log-rank test. To study the interac-
tionwith ATG, patients who received ATG were oversampled
with 50% of patients studied having received ATG.SNP analysis was performed on samples provided by the
NMDP Research Repository with whole genome ampliﬁca-
tion using the REPLI-g UltraFast Mini-Kit (QIAGEN, Chats-
worth, CA) and veriﬁed by RNASE-P analysis on the Taqman
7200. Genotyping of ampliﬁed DNA was performed with a
custom GoldenGate (Illumina, San Diego, CA) combined with
VeraCode technology on the BeadXpress according to the
manufacturer’s protocol (Illumina).
Each SNP was analyzed in multivariable models adjusting
for clinically signiﬁcant variables using the Cox’s propor-
tional hazards model. Due to multiple testing, P values
of < .005 were considered signiﬁcant. Reported P values
were not adjusted for multiple comparisons. Probability of
RFS and OS were calculated using the Kaplan-Meier esti-
mator from time of transplantation. The cumulative inci-
dence of NRM was calculated with relapse considered a
competing risk. The interaction with CTLA-4 SNPs and use of
ATG was also tested with 50% of the patient population
having received ATG as part of their conditioning regimen.
S. Sengsayadeth et al. / Biol Blood Marrow Transplant 20 (2014) 881e903902RESULTS
Table 1 lists patient-, transplantation-, and donor-related
variables for patients included in the study. The ﬁnal analysis
included 780 patients with a median follow-up of 63 months
for survivors. The median age of recipients and donors was
50 years (range, 18 to 74) and 34 (range, 18 to 61), respec-
tively. Ninety percent (n ¼ 706) of recipients and 82%
(n ¼ 639) of donors were of Caucasian descent. Eighty
percent of patients had been diagnosed with AML (n ¼ 624)
and 20% with advanced MDS (n ¼ 156). Conditioning was
61% myeloablative, 28% reduced-intensity, and 11% non-
myeloablative, with 74% receiving peripheral blood grafts.
Seventy-ﬁve percent were HLA-matched and 25% were
single-locus mismatched. Tacrolimus with methotrexate orFigure 1. Clinical outcomes stratiﬁed by donor CTLA-4 SNP rs4553808 genotype. (A)
adjusted probability of overall survival, (C) shows adjusted cumulative incidence of no
(E) shows adjusted cumulative incidence of relapse.mycophenolate mofetil GVHD prophylaxis was given to 62%,
cyclosporine-based prophylaxis to 15%, and 23% received
other regimens. By design, 50% of patients received ATG.
Genotyping showed that 552 (71%) were AA, 208 (27%) were
AG, and 19 (2%) were GG (AG, and particularly GG, were
associated with worse outcomes in the prior study).
Multivariable analysis adjusting for relevant donor and
recipient characteristics showed no signiﬁcant association
between SNP rs4553808 and OS, RFS, NRM, and the cumu-
lative incidence of acute GVHD, chronic GVHD, and relapse
(Figure 1). Multivariable analysis of the other 9 tagSNPs of
the CTLA-4 gene showed no association with primary trans-
plantation outcomes (all P values > .005). No interactionwas
found between CTLA-4 SNPs and use of ATG on outcomes.shows adjusted cumulative incidence of grades 2 to 4 acute GVHD, (B) shows
nrelapse mortality, (D) shows adjusted probability of relapse-free survival, and
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Understanding the intricate balance of T cell homeostasis
in the post-transplantation period remains an important
area of investigation. CTLA-4, an important immunologic
checkpoint, and its genetic variations have been of interest in
the HSCT realm because of its possible important role in
immune modulation, especially as it relates to GVHD and the
potency of the GVT effect. CTLA-4 SNPs have previously been
shown to be associated with RFS, OS, and incidence of GVHD
[5-9], as well as a possible surrogate marker for response to
donor lymphocyte infusion after HSCT [13]. This raised the
possibility that a personalized approach to HSCT donor se-
lection and conditioning regimens based on genetic variation
could be realized. However, previous studies that have
investigated CTLA-4 SNPs have produced discordant results,
likely because of small sample sizes and heterogeneous
cohorts that, in turn, make interpretation of the true inter-
action of CTLA-4 SNPS with transplantation outcomes difﬁ-
cult. The negative result from this present study highlights
this limitation and underscores the importance of validation
of preliminary genomic association studies in larger, more
homogenous cohorts [14].
The strength of our study is indeed thehomogeneity of our
patient population with regards to the disease and trans-
plantation type, as well as its large sample size, particularly
compared with previous similar studies. To our knowledge,
this study is the largest and most homogenous trans-
plantation cohort investigating genetic variation in CTLA-4,
although is should be noted that there were differences in
other variables, such as age, degree of HLA match, condi-
tioning regimens, and post-transplantation GVHD prophy-
laxis. Additionally, this large sample size allowed us to
perform an exploratory analysis of other CTLA-4 SNPs, as well
as study the interaction with ATG. Our methods included
increased stringency for statistical signiﬁcance due to mul-
tiple testing, lending further credence to the interpretation of
our results and ﬁnal conclusion.
Limitations of this study include that only donor genetic
variation of CTLA-4 was studied. Although, theoretically,
donor genetics likely plays a more important role in post-
transplantation T cell homeostasis, there certainly could be
an interactionwith recipient genetic variations that were not
accounted for. Secondly, because our study included only
patients with AML/MDS in the unrelated donor setting, the
application of our conclusion is restricted to such patients. It
is possible that other disease and transplantation types may
produce different results. Haplotypes of the CTLA-4 gene
were not studied as in some previous studies, and thus our
conclusions are limited only to the single SNP level with
regards to genetic variation. Finally, it is also possible that if
an interaction is present, the impact of a single poly-
morphism may simply be too small to inﬂuence such
expansive outcomes as NRM, RFS, and OS.
In conclusion, the observation from our previous pilot
study that SNP rs3554808 was an independent predictor of
transplantation outcomes was not conﬁrmed in this larger
study. Moreover, no other CTLA-4 SNPs in our exploratory
analysis were identiﬁed to be independent predictors of
outcomes. Data from this study support the conclusion thatdonor CTLA-4 SNPs are not associated with unrelated donor
HSCT outcomes in patients with AML and MDS. Though the
results of this study are negative, it should be considered
deﬁnitive in such patient populations. Future studies could
include investigation of genetic variation of CTLA-4 in other
disease and transplantation types, as well as other immune
checkpoints, such as PD-1, especially as clinical therapeutics
that target PD-1 evolve.ACKNOWLEDGMENTS
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